Moesin Expression in Clear Cell Renal Cell Carcinoma
Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
1 other identifier
observational
50
0 countries
N/A
Brief Summary
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2017
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedFirst Submitted
Initial submission to the registry
September 20, 2023
CompletedFirst Posted
Study publicly available on registry
September 28, 2023
CompletedSeptember 28, 2023
September 1, 2023
4.8 years
September 20, 2023
September 20, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Detection of Moesin in renal cell carcinoma
different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.
6 months
Interventions
Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
Eligibility Criteria
The present work will be performed on archived formalin-fixed, paraffin-embedded renal cell carcinoma tissue blocks that were belonged to 55 patients who were admitted to Sohag University Hospital because of loin/ back pain, from January 1st,2017 to December 31st, 2021. Radiological evaluation revealed renal neoplasms and patients underwent radical nephrectomies.
You may qualify if:
- All cases of ccRCC.
- Tissue blocks with material adequate for immunohistochemical evaluation.
- All cases with accessible clinical data.
You may not qualify if:
- Cases of renal neoplasms other than ccRCC.
- Patients who received preoperative chemotherapy or radiotherapy.
- Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
- Cases with insufficient/destructed material.
- Patients with inadequate clinical data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Maisa H Mohammed, MD
Study Record Dates
First Submitted
September 20, 2023
First Posted
September 28, 2023
Study Start
January 1, 2017
Primary Completion
October 31, 2021
Study Completion
December 31, 2021
Last Updated
September 28, 2023
Record last verified: 2023-09